Sofgen Pharma S.A PROCF
0.00
0.00
NaN
as of 24 Sep
- Market cap
- $114.0M
- P/E
- 0.0×
Follow PROCF
| Sep '19 | Dec '19 | Sep '20 | Dec '20 | Sep '21 | Dec '21 | Sep '22 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 985.00 | — | 0.00 | 0.00 | 0.00 | 11.57 | 13.38 | 10.54 | 5.76 |
P/S ratio |
— | 0.00 | — | 0.00 | 1.85 | 2.34 | 1.63 | 1.17 | 1.02 | 0.56 |
P/FCF ratio |
— | 0.00 | — | 0.00 | 0.00 | 70.51 | 0.00 | 0.00 | 5.78 | 3.16 |
P/Operating CF |
— | (142.51) | — | (1.75) | 28.64 | (70.14) | 122.96 | (72.80) | 11.78 | 6.44 |
P/B ratio |
— | 9.85 | — | 0.00 | 28.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | 9.85 | — | 0.00 | 279.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | — | 0.00 | 2.10 | 2.80 | 2.16 | 1.83 | 1.72 | 1.26 |
EV/EBITDA |
— | 0.00 | — | 1.93 | 3.70 | 13.40 | 10.62 | 27.63 | 8.08 | 5.91 |
EV/Operating CF |
— | (132.69) | — | (1,855.61) | 53.21 | 30.74 | 111.55 | 47.37 | 6.77 | 4.95 |
EV/FCF |
— | (132.69) | — | (71.16) | (666.08) | 84.48 | (49.59) | (43.61) | 9.74 | 7.13 |
Quick Ratio |
0.12 | — | 6.61 | 0.42 | 1.01 | 1.01 | 0.53 | 0.39 | 0.34 | 0.26 |
Current Ratio |
0.12 | — | 7.28 | 0.77 | 1.59 | 1.59 | 0.81 | 0.72 | 0.64 | 0.52 |
Net Debt/EBITDA |
1.83 | 0.00 | 1.10 | 5.92 | 2.12 | 2.22 | 4.27 | 9.88 | 3.29 | (7.21) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 132.15% | 54.83% | 56.65% | 62.13% | 69.23% | 67.88% | 66.83% |
Debt/Equity |
0.00 | — | 0.00 | (1.87) | (6.77) | (6.83) | (303.86) | (8.25) | (435.78) | (5.28) |
Asset Turnover |
0.00 | 2,694.25 | 0.00 | 1.18 | 1.00 | 0.89 | 0.89 | 0.89 | 0.93 | 0.85 |
Operating CF/Net income |
1.00 | (4.02) | 0.06 | (6.86) | (0.20) | (0.37) | 0.10 | 0.43 | 2.67 | (1.29) |
Capex/Depreciation |
0.00 | (0.74) | — | (1.05) | 0.00 | (1.57) | 0.00 | (1.93) | (1.80) | (1.25) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 562.96% | 0.00% | (501.00%) | 8.37% | 69.07% | 266.34% | (216.59%) | (189.76%) | (213.06%) | 258.60% | |
| (6.30%) | (14,108.67%) | (12.40%) | (3.72%) | (24.55%) | (21.83%) | 9.22% | 8.00% | 8.82% | (15.45%) | |
ROIC |
0.00% | 0.00% | (13.41%) | 18.23% | 0.00% | 29.10% | 0.00% | 2.71% | 15.21% | (17.51%) |
Return on Tangible Assets |
7.47% | 0.00% | (1,382.41%) | (67.80%) | (45.25%) | (55.20%) | 101.17% | (99.25%) | (60.27%) | 64.76% |
Average Days of Receivables |
— | 0.00 | — | 106.25 | 105.65 | 104.62 | 136.47 | 96.33 | 107.54 | 76.48 |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 44.66% | — | 38.69% | 40.33% | 40.33% | 48.66% | 49.03% | 45.63% | 59.67% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.10 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.07 |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | (3.97) | — | (8.26) | (0.12) | (0.21) | (0.25) | (0.42) | (0.46) | (0.84) |
Graham Number |
— | 0.00 | — | 41.18 | 0.00 | 3.01 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | 0.10% | — | (14.23%) | (24.88%) | (10.54%) | 8.64% | 7.47% | 9.49% | 17.36% |
Free Cash Flow Yield |
— | (0.73%) | — | (14.13%) | (0.17%) | 1.42% | (2.67%) | (3.57%) | 17.31% | 31.67% |
Revenue per Share |
0.00 | 3.34 | 0.00 | 3.41 | 3.63 | 4.17 | 4.05 | 3.99 | 4.20 | 3.73 |
Operating CF per Share |
0.00 | 0.70 | (0.15) | 0.74 | 0.18 | 0.38 | 0.04 | 0.15 | 1.07 | 0.88 |
Capex per Share |
0.00 | (0.12) | 0.00 | (0.18) | 0.00 | (0.24) | 0.00 | (0.32) | (0.32) | (0.25) |
Free Cash Flow per Share |
0.00 | 0.58 | (0.15) | 0.56 | 0.18 | 0.14 | 0.04 | (0.17) | 0.74 | 0.63 |
Cash per Share |
0.01 | 0.00 | 0.19 | 0.04 | 0.64 | 0.73 | 0.43 | 0.43 | 0.24 | 0.30 |
Shareholders Equity per Share |
0.00 | 0.00 | 1.00 | (2.62) | (0.33) | (0.39) | (0.01) | (0.37) | (0.01) | (0.52) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.00 | 1.00 | (2.62) | (0.33) | (0.39) | (0.01) | (0.37) | (0.01) | (0.52) |
Free Cash Flow |
(0.02) | 56.19 | (0.77) | 54.41 | 19.88 | 13.57 | 4.08 | (16.89) | 74.84 | 63.46 |
Working Capital |
(0.20) | — | 0.91 | (54.93) | 110.10 | 110.10 | (70.93) | (106.98) | (157.92) | (199.18) |
Capital Expenditures |
0.00 | (12.11) | — | (17.29) | (24.52) | (23.73) | (31.57) | (32.44) | (32.79) | (24.97) |
Net Current Asset Value |
(0.20) | — | (196.32) | (429.51) | (202.42) | (202.42) | (164.62) | (200.36) | (197.59) | (247.03) |
EV/EBIT |
— | 0.00 | — | 38.55 | 33.16 | 16.27 | 12.65 | 75.06 | 10.12 | 7.40 |
Capex to Sales |
0.00 | 0.04 | — | 0.05 | 0.00 | 0.06 | 0.00 | 0.08 | 0.08 | 0.07 |
Net Profit Margin |
0.00% | (5.24%) | 0.00% | (3.15%) | (24.62%) | (24.62%) | 10.38% | 8.96% | 9.52% | (18.27%) |
Price to Operating Income |
— | 0.00 | — | 0.20 | 3.46 | 13.58 | 9.54 | 48.22 | 6.00 | 3.28 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | — | 0.23 | 0.13 | 0.21 | 0.15 | 0.24 | 0.20 | 0.21 |
Cash ROIC |
(40.43%) | 0.00% | (13.01%) | 0.61% | (32.26%) | (11.95%) | (33.20%) | (17.63%) | 4.84% | (2.09%) |
Accounts Receivable Turnover |
— | 0.00 | — | 0.00 | 3.81 | 3.47 | 3.03 | 3.11 | 3.66 | 3.68 |
Accounts Payable Turnover |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 2.25 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | 0.00 | 2.42 | 2.19 | 1.93 | 1.71 | 1.84 | 2.04 |
Average Days of Payables |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | 167.41 | 166.59 | 166.59 | 207.48 | 216.65 | 200.06 | 153.24 |
Average Receivables |
— | — | — | — | 107.54 | 118.02 | 135.36 | 129.84 | 115.64 | 101.59 |
Average Payables |
— | — | — | — | — | — | 75.82 | — | — | — |
Average Inventory |
— | — | — | — | 71.86 | 79.43 | 88.13 | 98.30 | 100.79 | 89.18 |
Average Assets |
0.24 | 0.12 | 101.19 | 280.96 | 410.84 | 462.14 | 461.16 | 451.36 | 457.51 | 442.10 |
Average Common Equity |
0.00 | — | 2.50 | (124.84) | (146.04) | (37.87) | (19.64) | (19.04) | (18.93) | (26.41) |
Columns are period end dates